loss per share compar estim loss per share
primarili result higher estim oper expens driven
higher expens million higher estim
million due million invest viacyt collabor
adjust estim revenu time collabor
payment make chang revenu outlook
increas estim oper expens year
make chang oper expens estim
increas estim loss per share year due
modest adjust interest incom share outstand modestli
decreas estim loss per share year
crispr announc first patient enrol phase i/ii trial
-thalassemia enrol current open multipl site
europ trial design enrol patient
crispr announc expect initi clinic trial lead
allogen car-t cell therapi target toward malign
crispr also advanc two addit allogen car-t candid target
bcma multipl myeloma hematolog malign
octob uspto grant patent regent
univers california uc univers vienna emmanuel
charpenti ph co-own foundat intellectu properti relat
genom edit technolog intellia sublicens intellectu
properti uc univers vienna licens agreement
gene-edit compani focus
develop transform gene-
base medicin seriou diseas
proprietari
analyst certif import disclosur see disclosur
anticip commerci
product prior therefor estim collabor
agreement payment continu primari contributor
revenu estim crispr total
revenu grow compound-annual-growth-rate approxim next
six year increas million
accord proprietari databas averag forward
price-to-sal multipl biotechnolog sector current
appli industri multipl estim
revenu million discount estim revenu
risk failur arriv valu rang
crispr current stock price howev
acknowledg possibl upsid estim crispr
therapeut may also advanc program quickli
estim
enrol phase i/ii studi
ind submiss ye
expect time collabor program
conserv crispr gain stronger patent
posit appeal process could signific
upsid estim
biggest risk current collabor achiev regulatori
believ risk secur futur collabor predominantli
patent-rel crispr current weaker patent
posit rel
estim impact crispr fail advanc
current collabor point receiv earli regulatori
mileston payment fail secur addit collabor
agreement would estim revenu million
reduc valu dramat
perform rate anticip crispr continu form
collabor cluster regularli interspac short palindrom repeat crispr
technolog advanc current collabor later stage develop
compani crispr stage develop early-stag
commerci platform technolog develop stage clinic
program yet profit primarili focu potenti futur revenu valu
base expect grow sale receiv
mileston payment current collabor agreement enter addit
agreement estim total revenu grow million
case development-stag compani estim nonetheless carri degre
use estim revenu million appli averag forward
price-to-sal biotechnolog sector discount estim
revenu risk failur arriv valu rang current stock
price howev acknowledg possibl upsid estim crispr
therapeut may advanc collabor ahead expect may secur
collabor estim
analysi
loss per share compar estim loss per share
primarili result higher estim oper expens driven higher
 expens million higher estim million due
million invest viacyt collabor detail analysi provid
exhibit analysi compar prior period opco estim
crispr nasdaq-crsp incom statement million except per share data estimatedactualactu vs opco bp actuali chang bp chang product revenu relat good equiti method extinguish convert incom incom share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request crsp perform na
adjust estim revenu time collabor payment
make chang revenu outlook increas
estim oper expens year make chang oper
expens estim increas estim loss per share
year due modest adjust interest incom share outstand
modestli decreas estim loss per share year detail
analysi chang outlook provid exhibit
exhibit analysi chang estim sinc last report
crispr nasdaq-crsp incom statement million except per share data priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang product revenu relat good equiti method extinguish convert incom incom share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request crispr
compani announc websit
crispr announc first patient enrol phase i/ii trial
-thalassemia enrol current open multipl site
europ trial design assess safeti efficaci adult transfusion-
trial dose sequenti pend data initi two
patient trial open broader concurr enrol trial
design enrol patient
crispr announc fda lift clinic hold investig
new drug applic ind sickl cell diseas scd
submit earlier crispr partner vertex
previous receiv approv conduct trial multipl countri europ
well canada like trial -thalassemia first two patient trial
dose sequenti pend data initi two patient
trial open broader concurr enrol trial design enrol
patient note fda lift clinic hold sickl cell
anemia potenti upsid outlook
crispr announc expect initi clinic trial lead
allogen car-t cell therapi target toward malign
crispr also advanc two addit allogen car-t candid
target bcma multipl myeloma hematolog malign
solid tumor
septemb crispr announc collabor viacyt
focus discoveri develop commerci gene-edit
allogen stem cell therapi treatment diabet viacyt
compani state combin viacyt stem cell capabl
crispr gene edit capabl potenti enabl beta-cel
replac product may deliv durabl benefit patient without
trigger immun reaction note announc collabor
septemb us court appeal decis univers
california broad institut inc uphold decis ptab
interfer broad uc berkeley patent file
feder circuit determin ptab correctli termin
interfer rule board claim interfer uc
berkeley claim detail found note feder circuit court
uphold ptab decis crispr patent interfer disput
octob patent trademark offic uspto grant
 patent regent univers california uc
univers vienna emmanuel charpenti ph co-own
foundat intellectu properti relat genom edit
guid dual-guid format may use environ includ
eukaryot cell human anim plant cell optim format
modifi part guid rna interact nucleas
previous award patent cover method use
optim guid rna edit gene certain environ includ
eukaryot cell intellia sublicens intellectu properti uc
univers vienna licens agreement carib bioscienc inc
compani announc websit
octob crispr announc fda lift clinic hold
accept ind treatment sickl cell diseas scd
investig autolog gene-edit hematopoiet stem cell
therapi patient suffer sever hemoglobinopathi crispr
previous announc obtain approv
clinic trial applic multipl countri outsid us
-thalassemia scd compani reiter remain track
initi phase i/ii clinic studi scd end current
enrol patient transfus depend -thalassemia phase i/ii trial
-thalassemia europ note fda lift clinic hold sickl
cell anemia potenti upsid outlook
compani announc websit
crispr announc present poster societi immunotherapi
cancer confer novemb relat multiplex
edit product allogen car-t therapi
crispr also announc present poster upcom american
societi hematolog annual meet decemb
highlight develop preclin data allogen
shelf car-t cell target bcma patient multipl myeloma
product candidateindicationfilingexpect candidatestudyindicationexpect time edit cancersitc myelomaash crsp perform na
provid summari financi outlook full financi
model product detail avail upon request
crispr nasdaq-crsp leah rush cannestim sale earningsoppenheim co million except per share statement cell product revenu relat growth incom share share per share per share sheet stockhold statementoper cash flow per cash flow per compani data oppenheim co estimatesaddit inform avail upon request crispr
stock price compani mention report
